Literature DB >> 11706089

Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies.

M Giraud1, G Beaurain, A M Yamamoto, B Eymard, C Tranchant, P Gajdos, H J Garchon.   

Abstract

BACKGROUND: MG is an autoimmune disease of the neuromuscular junction. MG with thymus hyperplasia has been associated with, but not genetically linked to, the HLA-DR3 haplotype.
OBJECTIVE: To re-evaluate the association of HLA with MG in 656 patients with generalized disease and to test linkage of HLA to MG with thymus hyperplasia.
METHOD: Patients were genotyped for HLA-DRB1. Data analysis included case-control comparisons after subgrouping patients by thymus histopathology. The transmission of parental alleles to MG offspring with thymus hyperplasia was studied in simplex families using the transmission/disequilibrium test (TDT) as a test of linkage.
RESULTS: MG with thymus hyperplasia was positively associated with DR3 (OR = 4.5, p = 1 x 10(-6)) and negatively associated with DR7 (OR = 0.28, p = 1 x 10(-6)), based on both case-control comparisons and TDT. No association was detected with thymomas. Conversely, patients who lacked thymus anomalies but expressed anti-titin antibodies (ATA) had an increase of DR7 (OR = 2.08, p = 4 x 10(-3)) and a decrease of DR3 (OR = 0.33, p = 9 x 10(-3)).
CONCLUSIONS: The authors established linkage of HLA to MG and thymus hyperplasia, defining the MYAS1 locus. Moreover, DR3 and DR7, or closely linked genes, have opposing effects on MG phenotypes. Nonthymomatous patients with ATA may be a pathogenetically distinct subset of MG patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706089     DOI: 10.1212/wnl.57.9.1555

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia.

Authors:  Claire Vandiedonck; Geneviève Beaurain; Matthieu Giraud; Catherine Hue-Beauvais; Bruno Eymard; Christine Tranchant; Philippe Gajdos; Jean Dausset; Henri-Jean Garchon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

2.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

3.  Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.

Authors:  Peter K Gregersen; Roman Kosoy; Annette T Lee; Janine Lamb; Jon Sussman; David McKee; Kim R Simpfendorfer; Ritva Pirskanen-Matell; Frederik Piehl; Qiang Pan-Hammarstrom; Jan J G M Verschuuren; Maarten J Titulaer; Erik H Niks; Alexander Marx; Philipp Ströbel; Björn Tackenberg; Michael Pütz; Angelina Maniaol; Ahmed Elsais; Chantal Tallaksen; Hanne F Harbo; Benedicte A Lie; Soumya Raychaudhuri; Paul I W de Bakker; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Lennart Hammarstrom; Michael F Seldin
Journal:  Ann Neurol       Date:  2012-10-10       Impact factor: 10.422

Review 4.  Selective IgA deficiency in autoimmune diseases.

Authors:  Ning Wang; Nan Shen; Timothy J Vyse; Vidya Anand; Iva Gunnarson; Gunnar Sturfelt; Solbritt Rantapää-Dahlqvist; Kerstin Elvin; Lennart Truedsson; Bengt A Andersson; Charlotte Dahle; Eva Ortqvist; Peter K Gregersen; Timothy W Behrens; Lennart Hammarström
Journal:  Mol Med       Date:  2011-08-04       Impact factor: 6.354

5.  Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases.

Authors:  John D Rioux; Philippe Goyette; Timothy J Vyse; Lennart Hammarström; Michelle M A Fernando; Todd Green; Philip L De Jager; Sylvain Foisy; Joanne Wang; Paul I W de Bakker; Stephen Leslie; Gilean McVean; Leonid Padyukov; Lars Alfredsson; Vito Annese; David A Hafler; Qiang Pan-Hammarström; Ritva Matell; Stephen J Sawcer; Alastair D Compston; Bruce A C Cree; Daniel B Mirel; Mark J Daly; Tim W Behrens; Lars Klareskog; Peter K Gregersen; Jorge R Oksenberg; Stephen L Hauser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

Review 6.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

7.  Myasthenia Gravis.

Authors:  Michael Graves; Jonathan S. Katz
Journal:  Curr Treat Options Neurol       Date:  2004-03       Impact factor: 3.598

8.  Identifying alternative hyper-splicing signatures in MG-thymoma by exon arrays.

Authors:  Lilach Soreq; Adi Gilboa-Geffen; Sonia Berrih-Aknin; Paul Lacoste; Ariel Darvasi; Eyal Soreq; Hagai Bergman; Hermona Soreq
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

9.  Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Authors:  Michael F Seldin; Omar K Alkhairy; Annette T Lee; Janine A Lamb; Jon Sussman; Ritva Pirskanen-Matell; Fredrik Piehl; Jan J G M Verschuuren; Anna Kostera-Pruszczyk; Piotr Szczudlik; David McKee; Angelina H Maniaol; Hanne F Harbo; Benedicte A Lie; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Peter K Gregersen; Lennart Hammarstrom
Journal:  Mol Med       Date:  2015-11-10       Impact factor: 6.354

10.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.